Subscribe to our newsletter

  • All actions taken by Onyx Health will be in accordance with our Privacy Policy. You have the right to withdraw your consent at any time by contacting Onyx Health directly on 0191 640 3638

Industry Insight

The UK’s 10 Year Life Sciences Vision

By Onyx Health | 14th July 2021

At Onyx Health, we’re driven by our knowledge to create success for our clients across the Medtech, life science and pharmaceutical industries.  

One of the things that caught our eye recently was the publication of the Government’s UK Life Sciences Vision for the next ten years. 

The strategy will have big implications for UK life science companies over the next decade, providing innovation-led growth and investment opportunities. We all know that Government documents can be a tough read at times, so we’ve pulled together a brief overview of the strategy and its implications. Get in touch to find out how you can unlock the commercial opportunities in the Government’s life science strategy for your business.  

Background 

The Government recently published its new UK Life Sciences Vision, which sets out the key priorities for the sector spanning the next decade. It sets out a “bold vision” to tackle some of the biggest health problems facing the UK for a generation, placing a particular emphasis on cancer and dementia. 

One of the strategy’s key features is to harness the successes of the UK Vaccines Taskforce, using the private sector’s expertise to remove unnecessary bureaucracy to help tackle healthcare challenges. 

It emphasises the role of innovation and investment to drive growth within the life science sector and the need to tackle several priority health areas.   

Seven healthcare missions  

The strategy outlines seven critical healthcare missions that the Government will work in partnership to deliver across the sector over the next ten years. This will include an emphasis on preventing, diagnosing, monitoring and treating the disease early, using innovative clinical trials to develop breakthrough treatments to help save lives.  

 The seven missions are: 

1. Accelerating the pace of studies into novel dementia treatment. 

2. Enabling early diagnosis and treatments, including immune therapies such as cancer vaccines. 

3. Sustaining the UK’s position in vaccine discovery, development and manufacturing. 

4. Treatment and prevention of cardiovascular diseases and their major risk factors, including obesity. 

5. Reducing mortality and morbidity from respiratory disease in the UK and globally. 

6. Addressing the underlying biology of ageing. 

7. Increasing the understanding of mental health conditions, including work to redefine diseases and develop tools to address them. 

Comment  

The healthcare missions identified by the Government presents particular opportunities for life science companies working in the diagnostic and manufacturing sectors, as well as those with specialist expertise in key disease areas identified in dementia, cancer and cardiovascular disease.  However, it is unclear from the document how some of these objectives will be achieved in practice. A more detailed delivery plan is needed to give the sector greater peace of mind.  

Preconditions of success  

To realise these goals, the Government has identified four preconditions of success that must be met over the next decade.  

Comment 

The focus on investment and innovation is welcome news for the life science sector, which has experienced a period of uncertainty due to Brexit and the disruption caused to global supply chains during the COVID-19 crisis. Having an appropriate regulatory framework in place will also be important to foster a culture of innovation on a domestic level that avoids unnecessary constraints and ensures market access. 

Investment in Life Sciences 
Comment

The only funding guaranteed from the Life Sciences Investment Programme is £200m; whilst there are ambitions to deliver £1bn worth of funding, it remains to be seen whether this is an achievable or realistic goal. Whilst the additional funding via the Medicines and Diagnostics Transformation Fund may be potentially beneficial, £20m is a relatively small amount of capital allocation, which may limit its impact.   

Back to Blog

Next Story